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Abstract
Asthma is a common chronic illness that imposes a heavy burden on
all aspects of the patient’s life, including personal and health care cost
expenditures. To analyze the direct cost associated to uncontrolled
asthma patients, a cross-sectional study was conducted to determine
costs related to patients with uncontrolled and controlled asthma.
Uncontrolled patient was defined by daytime symptoms more than
twice a week or nocturnal symptoms during two consecutive nights or
any limitations of activities, or need for relief rescue medication more
than twice a week, and an ACQ score less than 2 points. A question-
naire about direct cost stratification in health services, including
emergency room visits, hospitalization, ambulatory visits, and asthma
medications prescribed, was applied. Ninety asthma patients were
enrolled (45 uncontrolled/45 controlled). Uncontrolled asthmatics
accounted for higher health care expenditures than controlled patients,
US$125.45 and US$15.58, respectively [emergency room visits
(US$39.15 vs US$2.70) and hospitalization (US$86.30 vs US$12.88)],
per patient over 6 months. The costs with medications in the last
month for patients with mild, moderate and severe asthma were
US$1.60, 9.60, and 25.00 in the uncontrolled patients, respectively,
and US$6.50, 19.00 and 49.00 in the controlled patients. In view of the
small proportion of uncontrolled subjects receiving regular mainte-
nance medication (22.2%) and their lack of resources, providing free
medication for uncontrolled patients might be a cost-effective strategy
for the public health system.
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Introduction
Asthma is one of the most common
chronic diseases and affects a million people
in the world (1). According to data of popu-
lation-based surveys there is a gap between
asthma management as stipulated by GINA
and the achievement of asthma control around
the world (2-6). These studies have shown
high levels of both emergency room visits
and hospitalization despite the availability
of effective therapies to achieve asthma con-
trol.
One of the most relevant socioeconomic
impacts of this disease is the heavy burden of
direct expenditures related to health care
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costs due to uncontrolled asthma, causing
unscheduled clinical visits, emergency room
attendance and hospitalizations. Asthma is
also a leading reason of lost school and
working days, dysfunction and retirement.
Improving asthma control reduces hospital-
ization costs, in contrast to an increase of
expenditures with maintenance medications
(7).
The costs associated with asthma man-
agement can be classified as direct, indirect
and intangible. Direct costs include expen-
ditures with health services: emergency de-
partment, hospitalization, ambulatory visits,
and asthma medications prescribed. Indirect
costs include costs resulting from missed
work or school days and days with restricted
activity at work, premature retirement and
death. The adverse impact of asthma on the
quality of life of the patients and on the
families, as well as the limitation of physi-
cal, emotional and intellectual development
is difficult to quantify, and therefore is re-
ferred to as intangible costs (8-12).
In Brazil, asthma was the third cause of
hospitalization in 2001 (DATASUS-govern-
ment database) and the total estimated cost
was US$35,000,000.00 spent every year with
public health services related to asthma (13).
However, the level of disease control, dis-
ease severity and medical resource utiliza-
tion among Brazilian asthmatics is poorly
documented and unknown.
Asthma control is hard to measure be-
cause the patients tend to underestimate the
severity of their condition and to overesti-
mate control (4). Analyses of direct cost
distribution due to asthma in a population
should help to estimate the achievement of
good asthma control.
The objective of the present study was to
measure the direct cost of health care for
asthmatic patients, to identify the main ex-
penditures according to asthma control, and
to determine the burden of the disease for
both the heath care system and family in-
come.
Patients and Methods
This is a cross-sectional study conducted
at the Hospital of the Federal University of
São Paulo. All consecutive patients attended
in the Emergency room and outpatient de-
partment with a diagnosis of asthma by GINA
criteria were invited to participate in the
study (14). The study was continued until a
number of 45 uncontrolled patients and 45
controlled patients from the outpatient clinic
was reached. This equal number was de-
fined in order to keep the same proportion of
influence on costs. The study was approved
by the Ethics Committee of the Institution
and all subjects gave written informed con-
sent to participate. Those who had other
concomitant severe lung diseases or more
than 5 pack-years of smoking were excluded
from the study.
The subjects were classified as having
mild, moderate and severe asthma based on
the definitions given below (14).
Mild
Symptoms more than once a week but
less than once a day, exacerbations possibly
affecting activity and sleep, nocturnal symp-
toms more than twice a month, and forced
expiratory volume in 1 s (FEV1) or peak
expiratory flow (PEF) ≥80% predicted.
Moderate
Daily symptoms, exacerbations possibly
affecting activity and sleep, nocturnal symp-
toms more than once a week, daily use of an
inhaled short-acting α2-agonist, and FEV1
or PEF 60-80% predicted.
Severe
Daily symptoms, frequent exacerbations,
frequent nocturnal asthma symptoms, limi-
tation of physical activity, FEV1 or PEF
≤60% predicted.
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The patients were stratified into controlled
and uncontrolled asthmatics based on the
clinical features of the disease. The con-
trolled asthmatics have daytime symptoms
less than twice a week or nocturnal symp-
toms less than once a week, no limitations of
activities, or need for relief rescue medica-
tion less than twice a week, and an Asthma
Control Questionnaire (ACQ) score less than
2 points. The uncontrolled asthmatics have
daytime symptoms more than twice a week
or nocturnal symptoms during two consecu-
tive nights or any limitations of activities, or
need for relief rescue medication more than
twice a week, and an ACQ score more than 2
points. The ACQ is a standardized question-
naire with seven simple questions about how
often the patient was bothered by asthma
symptoms in the past seven days. A zero
point score means well-controlled asthma,
and a six point score means uncontrolled
asthma (15). For a reliable determination of
the presence of inadequately controlled
asthma, the optimal cut-off point is 1.50 (posi-
tive predictive value = 0.88) (16).
All patients enrolled in the study com-
pleted an assessment interview which in-
cluded use of maintenance medication in the
last month, number of emergency room vis-
its, hospitalization, and admission to an in-
tensive care unit because of asthma during
the last 6 months, number of missed school
and work days during the last 6 months.
Cost
Direct costs over a 6-month study period
were related to asthma control, maintenance
medication use, and health care expendi-
tures. All costs were recorded in Brazilian
currency (real, R$) and converted to US$
(American dollar) based on an exchange rate
of 1US$ = 2.41R$ (17). The direct costs
included: a) medications, whose price was
taken from the Pharmaceutical Guide (18);
b) emergency room visits, hospitalizations
and admission to an intensive care unit be-
cause asthma was calculated based on reim-
bursement by the public health services for
each type of care: emergency room visit =
US$1.32 and complete hospitalization =
US$128.80 (13).
Statistical analysis
Descriptive statistical methods were used
to provide a general profile of the population
studied. The chi-square test was used to
compare proportions and the nonparametric
Mann-Whitney U-test was used to compare
continuous variables between groups. A P
value of <0.05 was considered to be statisti-
cally significant. Statistical analyses were
performed using the SPSS13 statistical soft-
ware. Because the cost analyses do not rec-
ommend statistical comparisons, we decided
to include at least 40 patients in each target
group of controlled and uncontrolled asthma
patients in order to describe the distribution
of direct cost expenditure for each status.
Results
Ninety asthma patients were enrolled in
the present study and their characteristics are
reported in Table 1. There were significantly
Table 1. Subject characteristics.
Controlled asthma group Uncontrolled asthma group
Gender (female/male) 39/6 30/15*
Age 48.0 ± 15 43.0 ± 19
Caucasian 36 36
Non-caucasian 9 9
Family income (US$) 329.5 ± 305 281.5 ± 187
Years of schooling 5.0 ± 3.8 6.5 ± 3.4**
<5 years/school (%) 66.7% 51.1%
>5 years/school (%) 33.3% 48.9%
Severity
Mild 14 17
Moderate 21 20
Severe 10 8
Use of inhaled corticoids (%) 82.2% 22.2%*
Data are reported as means ± SD, number or percent of 45 patients in each group. P <
0.05 compared to controlled group (*chi-square test, **t-test).
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more males in the uncontrolled group and also
a higher educational level in this group. The
controlled asthma group showed an average
PEF of 72.3% of the predicted value and the
average ACQ score was 1.34. These values
are compatible with controlled disease.
The severity of asthma was similar in
both groups. The majority of patients with
controlled asthma (82.2%) were users of
inhaled corticoids, as opposed to 22.2% of
uncontrolled patients.
The average direct costs per patient in the
uncontrolled asthma group were US$39.15
for emergency room visits, US$86.30 for
hospitalization and US$36.20 for mainte-
nance medication, while the average costs of
the controlled group were US$2.70 for emer-
gency room visits, US$12.88 for hospital-
ization and US$74.50 for maintenance medi-
cation (Figure 1).
Comparison of direct costs among se-
vere, moderate and mild asthmatics showed
that the highest expenditures for moderate
uncontrolled asthmatics were related to hos-
pitalization and emergency room visits
(US$10,69 and US$54,10; Table 2), while
the highest expenditures for the controlled
group were related to the medication con-
sumed by patients with severe asthma
(US$49,00; Table 3). The proportional dis-
tribution of medicine costs regarding sever-
ity is presented in Figure 2.
The maintenance medication for asthma
used up to 6.3% of the family’s monthly
income. The level of impact increased with
the severity of asthma. The controlled group
with severe asthma spent 18.2% of the fam-
ily income while the uncontrolled group spent
10.3% (Table 3).
The number of school and working days
lost was higher among the uncontrolled pa-
tients, 54 versus 30 days and 48 versus 12
days, respectively.
Discussion
The present study demonstrates that un-
Table 2. Emergency room (ER) visits and hospitalization costs according to asthma
severity (US$/per patient).
Controlled asthma group Uncontrolled asthma group
Visits to ER Hospital cost Visits to ER Hospital cost
(US$) (US$) (US$) (US$)
Mild 1.12 0.00 2.57 0.00
Moderate 0.93 0.00 10.69 54.10
Severe 0.65 12.88 25.89 32.20
Sub-total 2.70 12.88 39.15 86.30
Total 15.58 125.45
Hospital cost is reported as average cost per patient in US$, over 6 months.
Figure 1. Distribution of direct costs among controlled and uncontrolled asthma patients.
Figure 2. Cost of medication in the last month according to disease severity.
Table 3. Impact of medication cost on family income.
Severity Controlled asthma group Uncontrolled asthma group
Medication Income % of impact Medication  Income % of impact
Mild 6.50 310.40 2.1 1.60  334.60 0.5
Moderate 19.00 408.60 4.6 9.60  193.70 5.0
Severe 49.00 269.30 18.2 25.00 242.74 10.3
Total 74.50 988.35 7.5 36.20 771.09 4.7
Medication cost and income are reported for last month in US$.
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controlled asthmatic patients have higher
direct costs compared with controlled ones.
The major proportion of these direct costs in
uncontrolled patients was related to emer-
gency room visits and hospitalizations, whose
total expenditure was US$125.45, while for
the controlled patients it was US$15.58. It is
suggested that there is a gain area for signifi-
cant health care cost reduction by improving
the disease control.
The reduction in asthma mortality and
morbidity with the regular use of mainte-
nance medication has been well documented
(19-23). In our study, we observed that only
22% of the uncontrolled patients used in-
haled corticoids daily while 82% of the con-
trolled patients did so. The reduction of ex-
acerbations in the controlled asthma patients
as well as the lower direct cost with health
care assistance was a consequence of the use
of maintenance medication.
Among the controlled patients, the direct
cost was skewed toward more severe dis-
ease, while the uncontrolled patients with a
moderate level of asthma used more health
care attendance and spent more resources
compared with mild and severe patients.
This indicates that the total direct cost is
closely related to uncontrolled disease.
In our health system the drugs are not
free for patients, and therefore it is impera-
tive to estimate how medicine costs influ-
ence family resources. There is little infor-
mation regarding the financial impact of
asthma costs on family income. One of the
few published studies found that asthma care
expenditures accounted for an average of
6.4% of the family’s yearly income (24). In
our study we observed a similar impact, with
the cost of maintenance treatment represent-
ing 6.3% of the family income (23).
The cost of medicines might be a barrier
to asthma care in our poor population. Based
on this cost results, the Brazilian public health
system has been targeted to provide free
drug distribution to uncontrolled asthma pa-
tients. Although there would be an increase
in cost with the acquisition of medicines, the
total direct cost would be reduced by de-
creasing unscheduled visits, emergency at-
tendance and hospitalization. Moreover, this
recommended management of the disease
avoids dangerous consequences for under
treated asthma patients (24,25).
One of the limitations of the present study
is the difficulty to compare the amount of
money spent due to differences in economic
systems. The expenditures in Brazil are lower
compared to other studies; however, observ-
ing the direct cost oscillation between con-
trolled and uncontrolled patients it is pos-
sible to estimate the effect of asthma control.
The present study demonstrated that the
costs with controlled asthma affected the
total costs mainly by reducing health care
expenditures. On the other hand, the lack of
free distribution of medicines imposes a bur-
den on family income which might be a
barrier to asthma care.
The analysis of the direct cost due to
asthma may help to plan better strategies for
asthma management and prevention. Pro-
viding regular structured health care for
asthma patients would aid in obtaining good
control, reducing health care costs and im-
proving the quality of life, and would pro-
mote well-being and reduce the disease bur-
den on both the health care system and soci-
ety.
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